2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.133 (Poster) Clinical and Economic Outcomes Associated with Genomic Testing Strategies in Real World Data in Advanced Non Small Cell Lung Cancer (aNSCLC)

PP01.133 (Poster) Clinical and Economic Outcomes Associated with Genomic Testing Strategies in Real World Data in Advanced Non Small Cell Lung Cancer (aNSCLC)

Back to course

Pdf Summary

Genomic testing is increasingly important in the treatment of advanced non-small cell lung cancer (aNSCLC), but the association with overall survival (OS) and financial burden is not well understood. This study aimed to assess OS and costs in patients with aNSCLC utilizing genomic testing. The study utilized two databases: the Flatiron Health aNSCLC Enhanced Datamart database and the IQVIA PharMetrics Plus healthcare claims database.<br /><br />The study included patients diagnosed with aNSCLC between April 2019 and December 2021. Genomic testing methods were extracted from patient charts, including next-generation sequencing (NGS) and non-NGS genomic testing. Different testing strategy cohorts were identified, including upfront NGS, upfront non-NGS genomic tests, NGS after first-line therapy (1L), and no NGS testing.<br /><br />The study found that upfront NGS testing was associated with better OS compared to upfront non-NGS genomic testing, NGS after 1L, and no NGS testing in aNSCLC. Healthcare costs were comparable among the different testing strategies. These results highlight the need for education and wider accessibility of NGS testing.<br /><br />However, the study has limitations. The patients were primarily treated in community-based oncology practices, so the results may not be generalizable to the entire advanced NSCLC population. The PharMetrics Plus database represents the commercially insured US national population for patients under 65 years of age and may not be representative of the entire aNSCLC population.<br /><br />In conclusion, upfront NGS testing is associated with better OS compared to other testing strategies in aNSCLC. While there is a clinical benefit, healthcare costs are comparable among the different testing strategies. Further research is needed to validate these findings and understand the long-term outcomes associated with genomic testing in aNSCLC.

Asset Subtitle

Kate Lovett

Keywords

genomic testing

non-small cell lung cancer

overall survival

financial burden

Flatiron Health

IQVIA PharMetrics Plus

next-generation sequencing

NGS

healthcare costs

education